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This article overviewed the immunomodulation effects and clinical evidence of apheresis in 
renal diseases, especially primary and secondary glomerulonephritis.  A considerable 
permeability factor(s) derived from circulating T cells is speculated to have a crucial role in 
proteinuria of nephrotic syndrome (NS).  Plasma exchange (PE), immunoadsorption (IAPP) 
using Protein A sepharose cartridges, low density lipoprotein apheresis and lymphocyte 
apheresis (LCAP) were tried to remove such factors or pathogenic T cells.  Other glomerular 
diseases induced by specific antibodies such as anti-glomerular basement membrane antibodies, 
anti-neutrophil cytoplasmic antibodies and immune-complexes were also treated with PE, 
double filtration plasma apheresis, IAPP and LCAP.  The recommendations based on the 
evidence from recent randomized controlled studies have been established in apheresis therapy 
for the treatment of various glomerular diseases. 
 





Therapeutic application of apheresis therapy to a wide range of glomerular disorders occurred 
with the development of efficient plasma cell separation and following reports of the beneficial 
effect in anti-glomerular basement membrane (GBM) diseases since 1975 [1].  Since then new 
extracorporeal techniques such as immunoadsorption (IAPP), double filtration plasma 
apheresis (DFPP), low density lipoprotein (LDL) apheresis and lymphocyte or granulocyte 
apheresis (LCAP or GCAP) developed [2], apheresis therapies have been tried to remove 
pathological factors in nephritic syndrome such as anti-neutrophil cytoplasmic antibodies 
(ANCA) mediated vasculitis, and immune-complex diseases such as lupus nephritis to remove 
autoantibodies, immune-complexes, or pathological lymphocytes.   
In addition, glomerular permeability factor(s) derived from T cells may play a crucial role(s) in 
the protein excretion of nephrotic syndrome, especially minimal change nephrotic syndrome 
(MCNS) [3].  Circulating glomerular albumin permeability factor(s) were also detected in 
patients with native (primary) focal segmental glomerulosclerosis (FSGS) and recurrent FSGS 
after renal transplantation [4-5].  In such cases, plasma protein adsorption using Protein A 
sepharose cartridges [6-7] or anti-human immunoglobulin affinity immunoadsorption [7-8], 
plasma exchange (PE) [9-10], LDL apheresis [11] and/or LCAP [12] have been reported to be 
effective even for steroid-cyclosporin-A (CyA) resistant cases through removing the glomerular 
permeability factor(s) in some of these nephrotic patients. 
In this review, we overviewed the immunomodulation effects and clinical evidence of apheresis 
in various glomerular diseases, especially nephrotic syndrome and severe nephritic syndrome.  
 
2. Immunomodality of apheresis in glomerular diseases: Possible mechanisms 
The exact mechanisms by which apheresis is of benefit for glomerular diseases still remain 
investigated, however.  Possible actions of apheresis for renal diseases were summarized in 
Table 1.  In addition to removal of pathological agents such as antibodies, immune-complexes 
and/or immune-associated cells, removal of pro-inflammatory mediators including cytokines, 
chemokines and complements, and a demonstrated improvement of immune systems including 
reticuloendothelial function and Th1/Th2 balance of helper T cells have been postulated to 
contribute to the beneficial effects of apheresis [13-14].  In addition, infusion of normal plasma 
may itself have beneficial effects in some diseases such as thrombotic thrombocytopenic 
purpura (TTP) in which replacement of a deficient plasma may be the principal mechanism of 
PE independent of removal of circulating factors defined as anti-von Willebrand cleaving 
protease (ADAMTS-13) antibodies [14]. 
 
3. Apheresis techniques for renal diseases 
 The most important point is to select the appropriate methods for treating patients 
when we do extracorporeal immunomodulation for glomerular diseases.  The current technical 
aspects of apheresis are shown in Table 2.  In brief, soluble components were treated by 
standard (whole) PE, fractionated PE such as DFPP using plasma separator and fractionator, 
cryofiltration, and plasma adsorption that utilizes either protein A, dextran sulfate, tryptophan 
or phenylalanine as a ligand.  As for cellular components, centrifugation and specific 
adsorption cartridges are applied to separate lymphocytes and/or granulocytes with activated 
platelets.   
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4. Plasma exchange, DFPP and IAPP for soluble factors in glomerular diseases 
1) Anti-GBM disease 
The pathogenicity of anti-GBM antibodies towards the non-collagenous domain in C-terminus 
of the alpha 3 and/or 5 chain of type IV collagen that present in kidney and lung basement 
membrane.  Anti-GBM disease typically presents crescentic glomerulonephritis alone or with 
lung hemorrhage (Goodpasture’s syndrome).  The titer of circulating anti-GBM antibodies, 
which have been detected in more than 90% of patients, correlates disease activity.  Then, 
autoantibody removal by apheresis should be effective in concomitant with the suppression of 
antibody synthesis by immunosuppressive drugs.  Since the initial dramatic improvement in 
the PE-treated patients has been reported from Hammer-Smith Hospital in 1975, it has been 
accepted the efficacy of PE for anti-GBM disease.  However, only 2 controlled studies 
evaluated the efficacy of PE as an adjunct to conventional therapy.  Johnson et al. [15] 
compared the influence of PE with 4L every 3 days plus conventional immunosuppressive 
therapy (prednisolone and cyclophosphamide) to immunosuppression alone in a randomized 
controlled trial of 17 patients with anti-GBM nephritis.  They found a more rapid 
disappearance of circulating anti-GBM antibodies and a favorable renal function at the end of 
the study in the patients treated with PE (serum creatinine levels 4.4+/-0.6 mg/dL in combined 
therapy vs. 9.5+/-0.7 mg/dL in immunosuppression alone; p<0.05).  In addition, the results of 
more than 250 patients in uncontrolled studies, published over the past 3 decades, also 
suggested a favorable renal outcome in about 40% of patients.  Despite an effective apheresis, 
oligonuric patients and those on hemodialysis before apheresis rarely improve.  In such cases, 
apheresis was proposed only if lung hemorrhage was present.  Current strategy for anti-GBM 
disease is to do apheresis such as PE or DFPP in all patients dialysis independent before 
therapy and those with lung complication even on end-stage renal failure.   
 
2) ANCA related diseases 
The mechanisms by which apheresis is of benefit for small-vessel vasculitides remain obscure , 
however [16].  Recent studies revealed that ANCA itself could induce necrotizing 
glomerulonephritis in animal model, and that Th1 type helper T cell induced IgG subclasses, 
IgG1 or IgG1/IgG3 may relate the disease activity of ANCA-related vasculitis.  Hence, it seems 
reasonable to remove the circulating ANCA and to alter the Th1/Th2 type helper T cell balance 
by extracorporeal immunomodulation therapy in ANCA-related diseases.  The effectiveness of 
PE has been reported in some patients with rapidly progressive glomerulonephritis (RPGN), in 
which ANCA-associated vasculitis is the most common cause.  In 6 randomized controlled 
trials [17-22], there was no statistically significant benefit from plasma exchange in a whole 
group, however.  The significant difference was reported in the dialysis-dependent group with 
RPGN and systemic involvement, in which 10 out of 11 patients treated by PE and 3 of 8 
control patients recovered renal function by 4 weeks in previous studies.  In addition, good 
outcomes after PE have been reported in patients with lung hemorrhage and severe 
neurological diseases. In this notion, the multi-center European MEPEX trial 
(methylprednisolone pulse therapy versus PE as additional therapy for severe ANCA 
associated glomerulonephritis) had been attempted to define the role of PE in patients with 
ANCA related vasculitis and an initial creatinine level of more than 500 mol/L.  In this study, 
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PE was a positive predictor of dialysis independence after 12 mo for the entire patient group. 
PE remained a positive predictor when patients who were dialysis dependent at presentation 
were analyzed separately [22].  These results supporting a beneficial role of apheresis in whole 
small-vessel vasculitides is still small, but dialysis-dependent patients are the group who may 
have a benefit by PE in the presence of severe systemic diseases or high risks for complications 
such as infection. 
 
3) Lupus nephritis 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, which commonly 
involves glomerular disorders.  The prognosis of patients with lupus glomerulonephritis, 
especially proliferative glomerulonephritis the World Health Organization (WHO) class IV or 
ISN/RPS 2003 class IV-G and IV-S, is poor, despite treatment with immunosuppressive therapy 
in combination with glucocorticoids and cytotoxic drugs such as cyclophosphamide.  
Autoantibodies to double-stranded (ds)-DNA and other nuclear components are thought to 
participate in the initiation and progression of lupus nephritis.  Renal injury may result from 
either deposition or in situ formation of immune-complexes or direct injury of pathogenic 
autoantibodies or cytotoxic infiltrated cells such as macrophages and T cells.  In this notion, 
the use of apheresis therapy as more specific treatments to remove pathologically relevant 
autoantibodies or circulating cells seems rational [23].   
Various apheresis techniques such as PE, DFPP, adsorption apheresis using either protein A, 
dextran sulfate, tryptophan or phenylalanine as a ligand, have been explored for treatment of 
lupus nephritis [23].  Plasmapheresis therapy has been used, but there have been few 
controlled clinical observations of its efficacy.  In 1992, Lewis and the lupus nephritis 
collaborative study group [24] carried out a randomized, controlled trial comparing a standard-
therapy regimen of prednisone and cyclophosphamide (standard therapy) with a regimen of 
standard therapy plus plasmapheresis in 86 patients with severe lupus nephritis in 14 medical 
centers. The patients underwent PE 3 times weekly for 4 weeks.  As a result, 46 patients 
received standard therapy, and 40 patients received standard therapy plus plasmapheresis. 
Patients treated with PE had a significantly more rapid reduction of serum concentrations of 
antibodies against ds-DNA and cryoglobulins, however. Treatment with PE plus a standard 
therapy does not improve the clinical outcome in patients with SLE and severe nephritis, as 
compared with the standard therapy alone.  In addition, Wallace and collaboration group [25] 
were tried to access the efficacy of randomized controlled trial of methylprednisolone pulse 
therapy with synchronization cyclophosphamide or apheresis for proliferative lupus nephritis.  
Eighteen patients with WHO Class III or IV renal biopsies and chronicity indices less than 6 
points were prospectively randomized to receive 6 courses of parenteral cyclophosphamide over 
8 months along with prednisone.  No intergroup comparisons were significant. Then, this 
study concluded that the addition of synchronization apheresis to cyclophosphamide therapy 
does not improve the course of patients with proliferative lupus nephritis.  Other trials using 
adsorption apheresis showed the reduction of autoantibody titers and proteinuria, but these 
data on patients with lupus nephritis are limited.  Although apheresis therapy could modify 
the underlying pathogenic mechanisms, PE or other apheresis therapy offers no clear clinical 
benefit over conventional immunosuppressive therapy in severe proliferative lupus nephritis on 
the basis of currently available evidence.  However, apheresis therapy seems promising in 
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individual patients with acute life-threatening diseases such as catastrophic anti-phospholipid 
syndrome (CAPS) or who resistant to standard drug therapy, because of a rapid removal of 
circulating pathological factors.  
 
4) Nephrotic syndrome 
Proteinuria in patients with MCNS and FSGS is speculated to be caused by damage to the 
negative charge barrier of the glomerular capillary walls by some cationic substance [26]. 
Certain substances derived from serum, urine or lymphocytes of patients with MCNS have 
been reported as being responsible for the damage [3]. In addition, abnormal T cell function was 
also proposed as a pathogenic factor [27-28].  Savin’s group reported that plasmapheresis could 
diminish proteinuria and stabilize renal function in a part of patients with steroid-resistant 
idiopathic FSGS, suggesting that FSGS have some different local or systemic factor(s) 
unrelated to glomerular permeability [9-10, 28].  In addition, a recent prospective trial in 10 
patients at high-risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or 
prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PE treatments in the peri-
operative period.  Seven patients, including all 4 with first grafts and 3 of 6 with prior 
recurrence, were free of recurrence at follow-up (238-1258 days) [29]. 
Dantal et al. reported the active factor binds to protein A in FSGS, which was speculated as 
immunoglobulins, immunoglobulin fragments or proteins binding to Fc chains such as 
complement components, transforming growth factor-or other Ig-binding proteins [6, 8].  
Bosch and Wendler [30] summarized recent studies provide evidence that patients with 
recurrent FSGS after renal transplantation and those of primary FSGS can profit from PE or 
immunoadsorption.  They concluded that the indication of performing extracorporeal plasma 
therapy for recurrent FSGS would at best fall into Category II (accepted supportive therapy) 
according to the guidelines of the American Society for Apheresis, but for primary FSGS rather 
than into Category III (conflicting results, anecdotal reports).   
Hyperlipidemia, especially LDL, is an important factor for the outcome of steroid resistant 
nephrotic syndrome.  Muso et al. [11] firstly reported the effect of LDL apheresis in steroid-
resistant nephrotic syndrome, 6 patients with FSGS, one with MCNS, and one with 
membranous nephropathy (MN) and FSGS. The LDL apheresis, carried out 2-13 times (mean 
7.3) for one nephrotic episode and combined with steroid pulse therapy, led to rapid 
amelioration of hyperlipidemia.  Moreover, more than 50% reduction of proteinuria occurred 
(less than 3.5 g/day) in 6 nephrotic episodes (5 patients).  A significant elevation of serum 
albumin (more than 3.0 g/dl) was also obtained in five of these episodes.  In addition, 
Yokoyama et al. [31] found that LDL apheresis improved the response to steroid therapy in the 
patients of FSGS associated with nephrotic syndrome resistant to steroid, and that only 
electron microscopy was able to detect histological recovery in the patients who showed a 
decrease of proteinuria after LDL apheresis.  They also reported a case with primary FSGS in 
whom a complete remission of nephrotic state was achieved with LDL apheresis alone [32].  In 
the only prospective study reported by Stenvinkel and Swedish group in 2000 [33], LDL 
apheresis caused a rapid 30-40% decrease in serum cholesterol and plasma Lp (a) levels in 
patients with nephrotic syndrome. Their prospective study also suggested that short-term LDL 
apheresis might increase serum albumin levels in nephrotic patients.  Although the level of 
evidence is still low, it is expected that a rapid improvement of hypercholesterolemia by LDL 
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apheresis will provide more rapid relief from nephrotic state than immunosuppressive therapy 
alone in steroid-resistant nephrotic syndrome, especially primary FSGS. 
 
5. LCAP or GCAP for glomerular diseases, nephrotic syndrome and vasculitis 
In general, macrophages, cytotoxic and Th1 type helper T cells play a central role in the 
glomerular injury of crescentic glomerulonephritis.  In addition, glomerular permeability 
factor(s) derived from T cells may play a crucial role(s) in the protein excretion of nephrotic 
syndrome, especially MCNS and FSGS [3].  It has been reported that the removal of these 
pathogenic cells by lymphocytapheresis is effective in the treatment of autoimmune diseases or 
lymphocyte abnormalities, such as rheumatoid arthritis [34].  
 
1) Nephrotic syndrome 
After LCAP in nephrotic syndrome, the total number and population of peripheral blood WBC 
and CD4/CD8 ratio did not change, however, total number of lymphocytes, T cells, B cells and 
HLA-DR positive activated T cells decreased significantly in the response group.  The 
alteration of lymphocyte subsets was not found in the non-response group after LCAP.  No 
adverse effects were recorded during or after LCAP in any patients.  Proteinuria tended to 
decrease at 2 weeks post-treatment (8.2±1.8g/day before and 5.6±1.3 g/day at 2 weeks).  
Especially, patients with MCNS or FSGS showed good response to LCAP resulting in dramatic 
decrease of daily proteinuria.  Urinary protein/creatinine ratio also decreased between –30% 
and –94% in these cases.  Finally, complete or partial remission (proteinuria <1.0 g/day) was 
seen in patients treated by LCAP and following immunosuppressive or supportive therapy. In 
the results of LCAP [12], the serum levels of immunoglobulins, complements or lipids only 
changed in a small part even in the response group, suggesting that the mechanism of LCAP 
may be different from those of plasma protein adsorption using Protein A sepharose cartridges 
[6-7], anti-human immunoglobulin affinity immunadsorption [7-8], or LDL apheresis [11] as 
previously described.  However, impaired size barrier of the glomerular capillary walls causing 
the increased glomerular protein permeability could not be improved by LCAP [12].    
 
2) Crescentic glomerulonephritis with ANCA-associated vasculitis or IgA nephropathy  
Furuta et al. [35] investigated the efficacy of LCAP for treatment of RPGN, in comparison with 
steroid-pulse treatment.  They enrolled 24 patients with RPGN proven by biopsy in a 
prospective randomized study. The 12 in the LCAP group completed 9 LCAP sessions of 3 
consecutive weeks, with a Cellsorba cartridge (CS-120).  The other 12 controls received 1 g of 
methylprednisolone for 3 consecutive days in each of 3 consecutive weeks.  All patients 
received prednisolone (20 mg/day) and cyclophosphamide (50 mg/day).  The patients in LCAP 
group were 7 with IgA nephropathy and 5 with pauci-immune; and for 5 and 7 of those in the 
steroid-pulse group, respectively. The LCAP group showed significant improvements in renal 
function and proteinuria.  The ratio of CD4 to CD8 cells before and after the treatment showed 
no significant change in the lymphocytapheresis group, but the CD14/3 ratio substantially 
lower, suggesting this maneuver removed mainly CD8 and CD14 cells. They concluded that 
LCAP is more effective than steroid-pulse treatment for reduction of glomerular injury due to 
RPGN, as an effect of its selective removal of CD8 and CD14 cells.  In addition, Hasegawa et 
al [36] also reported the efficacy of cytapheresis for the treatment of RPGN caused by 
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myeloperoxidase (MPO)-ANCA-associated vasculitis, in comparison between a cytapheresis 
group and a steroid pulse group.  In their study, the cytapheresis group included 10 patients 
who were treated by GCAP with the Adacolumn in 5 patients and other 5 patients by LCAP 
with the Cellsorba.  In the cytapheresis group, the mortality rate by infection could be reduced 
at 1 year after treatment. 
 
6. Conclusions 
In aspect of immunomodulation, apheresis therapies not only accelerate the disappearance of 
circulating pathogenic factors such as autoantibodies, circulating permeability factor(s) and T 
cells, but also be able to modulate the immune response in backgrounds of glomerular diseases.  
It seems reasonable to conclude that removal of the circulating pathogenic factors by apheresis 
is an effective adjunct to conventional therapy in severe glomerular diseases.  In future, 
prospective randomized trials with a proper statistical evaluation will define the exact effects of 
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Table 1: Possible mechanisms of apheresis in renal diseases. 
 
#1 Removal of pathological circulationg factors, abnormal factors or physiologic factors in excess: 
1) Antibodies: anti-GBM diseases, ANCA associated diseases, lupus nephritis (anti-DNA), anti-phospholipid diseases 
2) Immune-complexes: lupus nephritis, cryoglobulinemia 
3) Dysproteins: macroglobulinemia, myeloma, amyloid-A protein, LDL (FSGS) 
4) Toxic factors: endotoxin, permeability factors? (MCNS, FGSS) 
5) Activated lymphocytes: vasculitis, nephrotic syndrome (MCNS, FSGS) 
 
#2 Replacement of deficient plasma factors: 
1) Thrombotic thrombocytopenic purpura: ADAMTS-13 
 
#3 Other effects on the immune system: 
1) Removal of inflammatory mediators: cytokines/chemokines, cannabinoids 
2) Improvement of reticuloendothelial system function 
3) Effects of immune regulation                                              
 
GBM, glomerular capillary basement membrane; ANCA, anti-neutrophil cytoplasmic antibodies; LDL, low-density lipoprotein; FSGS, 





Table 2: Application of apheresis techniques for renal diseases 
 
Procedure  Ligands or materials  Removed or adsorbed factors      
Plasma exchange Replacement of plasma* Autoantibodies, CIC, dysproteins 
 
Double filtration  Plasma fractionator   CIC, autoantibodies, dysproteins 
 
Cryofiltration  Plasma fractionator   Cryoproteins 
 
Plasma adsorption Phenylalanine   Anti-DNA, CIC 
    Dextran sulfate   Anti-DNA, CIC, lupus anticoagulants, LDL 
   Protein A   IgG, CIC, permeability factors (?) 
   Anti-IgG Fc   IgG, CIC, permeability factors (?) 
 




LCAP**  Lymphocyte separators  Lymphocytes, activated platelets 
GCAP*** Granulocyte separators  Granulocytes 
 
*, centrifugal method or plasma separator; **, lymphocytapheresis, ***, granulocytapheresis 




Table 3: Evidence on apheresis therapy in glomerular diseases. 
Diseases  Methods Study Design(N)  Level of Results 
       (references, ref.) evidence 
 
Anti-GBM  PE  RCT (1) (ref.15) 2  Better renal survival with PE 
 
RPGN   PE  RCT (6) (ref.17-22) 1-3  No benefit for entire group in 4/5 trials (80%), 
Discontinuation of dialysis more on PE in 3/6 trials 
(50%) 
More effective than steroid-pulse therapy in ANCA 
vasculitis, free from HD (19/35, 54% vs. 11/34, 
32% in MEPEX trial) 
   LCAP  RCT (1) (ref.35) 2  More effective than steroid-pulse therapy 
 
Lupus nephritis  PE  RCT (5) (ref.24-25) 2-3  Early disappearance of autoantibodies 
          No benefit for long-term clinical outcome 
 
FSGS  Primary  PE  UCT (3) (ref.30) 5-6  Remission in 11/20 patients (55%) 
   LDL-A  UCT (2) (ref.11,31) 5  Remission in 10/21 patients (48%) 
   LCAP  UCT (1) (ref.27) 6  Remission in 2/3 patients (67%) 
 
Recurrent PE  UCT/RHT(5) (ref.10,30) 4-6  Remission in 19/29 patients (66%) 
   Protein A UCT (3) (ref.6-7) 5  Short-term remission in 10/11 patients (91%) 
          Long-term remission in 2/8 patients (25%) 
   LCAP  Case study*  6  Remission in a renal transplanted case  
 
  Prevention PE  UCT(1) (ref.29)  5  No recurrence in 7/10 (70%) of high risk group 
 
Anti-GBM, anti-glomerular basement membrane disease; RPGN, rapidly progressive glomerulonephritis; FSGS, focal segmental 
glomerulosclerosis; PE, plasma exchange; LCAP, lymphocytapheresis; LDL-A, low density lipoprotein apheresis; RCT, randomized 
controlled trial; UCT, uncontrolled trial; RHT, retrospective historical controls. *: a recent case in our center 
